Should I buy West Pharmaceutical Services (WST) stock or is it too late?

West Pharmaceutical Services · Health Care · price $346

See the full West Pharmaceutical Services (WST) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $365 (+5.5 %), call made on July 10, 2026, maturing on July 10, 2027 (49 d ago).

The 4 reliable analysts $383+11 %

The 3 other firms $425+23 %

How to read it: the 4 reliable firms are not filtered by optimism — 4 aim above the price, 0 below, hence their $383 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on West Pharmaceutical Services

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Keybanc	55 %	+6.4 %	11	$390 +13%
B of A Securities	29 %	-22.8 %	7	$355 +3%

In short — Should you invest in West Pharmaceutical Services? Is it too late, still worth it? Analysts are overwhelmingly positive (86% buy, median target $400, i.e. +16%), and the most reliable on WST targets even higher. But the valuation is stretched (P/E ~45), it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

86% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
Median price target $400, i.e. +16% from the current price ($346).
The most reliable firm on WST, Evercore ISI Group (100% hit rate, 2 scored calls), targets $425 (call made on July 27, 2026, maturing on July 27, 2027) (+23%) in its most recent call, and $390 (call made on October 23, 2025, maturing on October 23, 2026) (+13%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 1 is neutral.
High valuation (P/E ~45): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
Negligible dividend (0.2% yield): your return depends mostly on price appreciation.

The analyst consensus on WST

Median target $400 (+16%) · 7 ratings · Buy consensus

Strong Buy00%

Buy686%

Hold114%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in West Pharmaceutical Services now?

We won't decide for you. The facts: 86% of analysts rate it a buy, median target $400 (+16%), and Evercore ISI Group (most reliable on WST, 100%) targets $425. Weigh that against valuation (P/E ~45). This is not personalized advice.

Is it too late to invest in West Pharmaceutical Services?

Not according to analysts: the median target ($400) is still +16% above the current price ($346) (most reliable on WST: Evercore ISI Group, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is West Pharmaceutical Services still worth investing in?

It depends on the gap between the price ($346) and its estimated value: analysts target $400 on median (+16%), with 86% buys (most reliable on WST: Evercore ISI Group, 100%). Cross-check with their real reliability on WST and the cautions above. Information, not advice.

What's the main risk in buying WST?

The consensus is not unanimous: of 7 ratings, 1 is neutral.

→ Go deeper: the full West Pharmaceutical Services profile (consensus, analyst reliability, price target, performance).